Regentis Biomaterials
RGNT
3 hedge funds and large institutions have $1.69M invested in Regentis Biomaterials in 2026 Q1 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
10.65% more ownership
Funds ownership: 0% → 10.65% (+11%)
0% more funds holding
Funds holding: 3 → 3 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
11% less capital invested
Capital invested by funds: $1.89M → $1.69M (-$206K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.44M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$1.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$127K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$70.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACM
1
AIGH Capital Management
Baltimore,
Maryland
| $917K | +$1.44M | +300,000 | New |
|
|
RA
2
Rosalind Advisors
Toronto,
Ontario, Canada
| $768K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $1.02K | +$1.6K | +334 | New |
|
|
WAM
4
Warberg Asset Management
Winnetka,
Illinois
| – | -$127K | -19,093 | Closed |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$70.2K | -10,412 | Closed |
|
RGNT Hedge Fund Activity: Q1 2026 in Review
3 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Regentis Biomaterials (RGNT) for Q1 2026, worth a combined $1.69M — down 11% from $1.89M a quarter earlier.
Fund positioning in RGNT was balanced in Q1 2026: 2 funds opened new positions, 2 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was AIGH Capital Management, opening a new position worth an estimated $1.44M. The largest seller was Warberg Asset Management, exiting entirely with an estimated $127K sold.
- 3 institutional investors held Regentis Biomaterials (RGNT) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $1.69M of Regentis Biomaterials stock for Q1 2026, down 11% quarter-over-quarter.
- 2 funds opened new Regentis Biomaterials positions in Q1 2026 and 2 closed out, a net change of 0 holders.
- The largest Regentis Biomaterials buyer in Q1 2026 was AIGH Capital Management, an estimated $1.44M added.
- The largest Regentis Biomaterials seller in Q1 2026 was Warberg Asset Management, an estimated $127K sold.
Based on aggregated 13F filings for Q1 2026.